
Medpace Holdings (MEDP) Stock Forecast & Price Target
Medpace Holdings (MEDP) Analyst Ratings
Bulls say
Medpace Holdings is poised for robust growth, with expected passthrough revenues projected to increase by 200-300 basis points in the second half of the year compared to elevated levels in the second quarter. The company has reported strong performance in the first quarter, highlighted by a higher request-for-proposal (RFP) volume, which underscores demand for its services. Furthermore, Medpace anticipates a favorable book-to-bill ratio, expected to return to above 1.15x in the third quarter, indicating strong order flow and a healthy pipeline for future revenue.
Bears say
Medpace Holdings has reported a concerning trend in its backlog cancellations, which increased to levels currently at or above the upper range of what the company considers normal, although there was a slight decrease in recent quarters. The company's future revenue growth projections for Direct Service remain uncertain, as management states it is too early to quantify potential outcomes, despite projecting a stable performance in 2026. Updated adjusted EBITDA estimates for 2025 and 2026 reflect an increase to $521 million and $550 million, respectively; however, this is accompanied by ongoing hiring in direct service costs and a decline in passthroughs anticipated for 2026, indicating potential financial strain and operational inefficiencies.
This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares